Mirador Capital Partners LP Acquires 1,010 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Mirador Capital Partners LP raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 1.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 65,636 shares of the biopharmaceutical company’s stock after buying an additional 1,010 shares during the period. Mirador Capital Partners LP owned about 0.06% of Cytokinetics worth $3,088,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. boosted its position in Cytokinetics by 65.6% in the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 238 shares during the last quarter. Blue Trust Inc. boosted its position in Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 680 shares during the last quarter. Values First Advisors Inc. bought a new position in Cytokinetics in the 3rd quarter valued at $54,000. Quarry LP lifted its stake in shares of Cytokinetics by 233.3% in the 2nd quarter. Quarry LP now owns 2,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,400 shares during the period. Finally, Avior Wealth Management LLC raised its stake in Cytokinetics by 57.1% during the 3rd quarter. Avior Wealth Management LLC now owns 3,999 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 1,454 shares during the period.

Cytokinetics Trading Down 1.4 %

Cytokinetics stock opened at $46.20 on Thursday. The stock has a 50-day simple moving average of $50.01 and a 200 day simple moving average of $53.33. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The stock has a market capitalization of $5.45 billion, a P/E ratio of -8.59 and a beta of 0.82. Cytokinetics, Incorporated has a 52 week low of $44.49 and a 52 week high of $86.63.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. The firm’s revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.35) EPS. Analysts expect that Cytokinetics, Incorporated will post -5.23 earnings per share for the current year.

Insiders Place Their Bets

In other Cytokinetics news, Director Wendall Wierenga sold 742 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $48.61, for a total transaction of $36,068.62. Following the completion of the sale, the director now directly owns 24,559 shares in the company, valued at $1,193,812.99. This trade represents a 2.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $51.91, for a total transaction of $378,943.00. Following the completion of the sale, the executive vice president now owns 114,920 shares of the company’s stock, valued at approximately $5,965,497.20. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 52,216 shares of company stock worth $2,707,436 over the last three months. Insiders own 3.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Monday, December 2nd. JMP Securities reissued a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research note on Tuesday. Mizuho lifted their price target on Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Friday, January 10th. Finally, Royal Bank of Canada raised their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $83.64.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.